Natera, Inc. (NASDAQ:NTRA) Shares Sold by Mission Wealth Management LP

Mission Wealth Management LP reduced its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 3.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,086 shares of the medical research company’s stock after selling 145 shares during the quarter. Mission Wealth Management LP’s holdings in Natera were worth $374,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NTRA. Norges Bank acquired a new stake in Natera during the 4th quarter worth $83,970,000. American Century Companies Inc. increased its stake in Natera by 115.7% in the third quarter. American Century Companies Inc. now owns 1,654,303 shares of the medical research company’s stock valued at $73,203,000 after purchasing an additional 887,409 shares during the period. Perceptive Advisors LLC increased its stake in Natera by 289.7% in the fourth quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock valued at $53,258,000 after purchasing an additional 632,047 shares during the period. Vanguard Group Inc. increased its stake in Natera by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock valued at $687,280,000 after purchasing an additional 588,147 shares during the period. Finally, Massachusetts Financial Services Co. MA acquired a new position in Natera in the fourth quarter valued at $27,626,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Natera

In other news, insider Daniel Rabinowitz sold 787 shares of the business’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $91.38, for a total value of $71,916.06. Following the completion of the transaction, the insider now owns 205,552 shares of the company’s stock, valued at $18,783,341.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, insider Daniel Rabinowitz sold 787 shares of the business’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $91.38, for a total value of $71,916.06. Following the completion of the transaction, the insider now owns 205,552 shares of the company’s stock, valued at $18,783,341.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Gail Boxer Marcus sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $110.17, for a total transaction of $220,340.00. Following the completion of the transaction, the director now directly owns 18,634 shares of the company’s stock, valued at approximately $2,052,907.78. The disclosure for this sale can be found here. Insiders have sold 201,770 shares of company stock valued at $20,023,161 over the last quarter. Corporate insiders own 7.60% of the company’s stock.

Natera Price Performance

NTRA stock traded up $1.10 during trading on Friday, reaching $112.74. 826,461 shares of the company were exchanged, compared to its average volume of 973,641. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $117.23. The company has a market cap of $13.84 billion, a P/E ratio of -36.13 and a beta of 1.48. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.98 and a current ratio of 4.12. The stock’s 50 day moving average price is $106.53 and its 200 day moving average price is $87.43.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.16. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The company had revenue of $367.70 million for the quarter, compared to the consensus estimate of $316.31 million. During the same quarter in the prior year, the firm earned ($1.23) earnings per share. The company’s revenue for the quarter was up 52.1% compared to the same quarter last year. As a group, analysts predict that Natera, Inc. will post -2.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

NTRA has been the topic of a number of recent research reports. TD Cowen lifted their price objective on shares of Natera from $123.00 to $137.00 and gave the company a “buy” rating in a research note on Friday, May 10th. Sanford C. Bernstein upgraded shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price objective on the stock in a research note on Friday, April 5th. BTIG Research lifted their price objective on shares of Natera from $100.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, May 13th. The Goldman Sachs Group boosted their price target on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. Finally, Jefferies Financial Group started coverage on shares of Natera in a research note on Monday, June 3rd. They set a “buy” rating and a $142.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $101.19.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.